A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AXA1665 IN SUBJECTS WITH LIVER CIRRHOSIS AND PRIOR OVERT HEPATIC ENCEPHALOPATHY (EMMPOWER)
- Registry ID
- AXA1665-101
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- AXCELLA HEALTH, INC
- Start date
- 2021-08-16
- Last update
- 2021-05-27
Conditions
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFECT OF SELADELPAR ON CLINICAL OUTCOMES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND COMPENSATED CIRRHOSIS
- A PHASE III DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL TO EVALUATE LIVER-RELATED CLINICAL OUTCOMES AND SAFETY OF ONCE WEEKLY INJECTED SURVODUTIDE IN PARTICIPANTS WITH COMPENSATED NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (NASH/MASH) CIRRHOSIS
- EFFECTS OF NNC0194-0499 ALONE AND IN COMBINATION
WITH SEMAGLUTIDE, OF SEMAGLUTIDE ALONE, AND OF CAGRILINTIDE ALONE AND IN COMBINATION
WITH SEMAGLUTIDE ON LIVER DAMAGE AND ALCOHOL USE IN PEOPLE WITH ALCOHOL-RELATED LIVER
DISEASE
- A PHASE III RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELAFIBRANOR 80 MG ON LONG-TERM CLINICAL OUTCOMES IN ADULT PARTICIPANTS WITH PRIMARY BILIARY CHOLANGITIS (PBC)
- A SEAMLESS, ADAPTIVE, PHASE 2B/3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, INTERNATIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF BELAPECTIN (GR-MD-O2) FOR THE PREVENTION OF ESOPHOGEAL VARICES IN NASH CIRRHOSIS
View on source registry